Polymeric micelle technology may enhance drug delivery to solid tumors. Thus, polymeric micelle technology enables translation of promising anticancer combinations into phase I clinical trials as unique nanomedicines, including Triolimus. Read more


The heterogeneity and evolutionary flexibility of cancer cells has largely rendered monotherapy of cancer with single targeted agents futile. To address this challenge, molecular multi-targeting has emerged as a key concept in cancer care. Two distinct approaches to molecular multitargeting can be pursued. Read more